SCHEMBL1706229

SCHEMBL1706229

CC(=O)c1ccn(Cc2nc(C(=O)Cl)co2)n1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.48
RAB9A P51151 7/20 0.36
NPC1 O15118 6/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
HDAC6 Q9UBN7 2/20 0.35
HRH3 Q9Y5N1 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HDAC1 Q13547 1/20 0.32
SMN1; SMN2 Q16637 4/20 0.31
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 1/20 0.30
DAGLA Q9Y4D2 1/20 0.30
KDM4C Q9H3R0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707155 0.88 FPR2 (0.51) FPR2RAB9ANPC1KMT2AMEN1
SCHEMBL2685053 0.87 FPR2 (0.48) FPR2RAB9ANPC1KMT2AMEN1
SCHEMBL13254733 0.84 FPR2 (0.50) FPR2RAB9ANPC1KMT2AMEN1
SCHEMBL2685055 0.83 FPR2 (0.44) FPR2RAB9ANPC1KMT2AMEN1
SCHEMBL1705802 0.83 FPR2 (0.45) FPR2RAB9ANPC1KMT2AMEN1
SCHEMBL27882081 0.82 FPR2 (0.44) FPR2RAB9ANPC1KMT2AMEN1
SCHEMBL27882139 0.81 FPR2 (0.45) FPR2RAB9ANPC1KMT2AMEN1
SCHEMBL1167220 0.80 FPR2 (0.51) FPR2KMT2AMEN1HDAC6HRH3
SCHEMBL1166765 0.76 FPR2 (0.48) FPR2KMT2AMEN1CYP1A2CYP2D6
SCHEMBL1706422 0.73 FPR2 (0.44) FPR2RAB9ANPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 FPR2 156/4885RAB9A 4168/4885NPC1 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.